Review



bnp levels  (Abbott Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Abbott Laboratories bnp levels
    Higher <t>Elevated</t> <t>Troponin-I</t> (High-Sensitivity Cardiac Troponin I) Levels Are Associated With Reduced Ejection Fraction (A) High-sensitivity cardiac troponin I (hs-cTnI) and (B) B-type natriuretic peptide <t>(BNP)</t> levels were measured at baseline (pretreatment) and various post-treatment (3, 6, 12, and 24 months). The red line represents mean values at each time point; fold changes were calculated relative to the baseline. Individual patient trajectories are shown as gray lines, with the mean fold change highlighted in red. Longitudinal changes relative to baseline were analyzed using linear mixed-effects models accounting for within-patient correlation, with baseline-referenced post hoc contrasts adjusted for multiple comparisons. Fold changes of (C) LVESV, (D) LVEDV, (E) LVEF, and (F) LVS′ were relative to baseline over time points (3, 6, 12, 24, 30, and 36 months) in patients stratified by high-sensitivity cardiac troponin I levels: troponin ≥0.028 (red line) and troponin <0.028 (blue line). Each point represents an individual patient, with means shown by the lines for each group, and shaded areas represent the 95% CI. Between-group differences over time were analyzed using repeated-measures models accounting for within-patient correlation, with P values adjusted for multiple comparisons. Statistical significance is indicated by asterisks. Statistical significance is indicated by asterisks (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). Abbreviations as in .
    Bnp Levels, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bnp levels/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    bnp levels - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "Methylated PIH1D1 as a Heart-Specific Biomarker for Anthracycline-Induced Cardiac Remodeling in Breast Cancer Patients"

    Article Title: Methylated PIH1D1 as a Heart-Specific Biomarker for Anthracycline-Induced Cardiac Remodeling in Breast Cancer Patients

    Journal: JACC: Basic to Translational Science

    doi: 10.1016/j.jacbts.2026.101510

    Higher Elevated Troponin-I (High-Sensitivity Cardiac Troponin I) Levels Are Associated With Reduced Ejection Fraction (A) High-sensitivity cardiac troponin I (hs-cTnI) and (B) B-type natriuretic peptide (BNP) levels were measured at baseline (pretreatment) and various post-treatment (3, 6, 12, and 24 months). The red line represents mean values at each time point; fold changes were calculated relative to the baseline. Individual patient trajectories are shown as gray lines, with the mean fold change highlighted in red. Longitudinal changes relative to baseline were analyzed using linear mixed-effects models accounting for within-patient correlation, with baseline-referenced post hoc contrasts adjusted for multiple comparisons. Fold changes of (C) LVESV, (D) LVEDV, (E) LVEF, and (F) LVS′ were relative to baseline over time points (3, 6, 12, 24, 30, and 36 months) in patients stratified by high-sensitivity cardiac troponin I levels: troponin ≥0.028 (red line) and troponin <0.028 (blue line). Each point represents an individual patient, with means shown by the lines for each group, and shaded areas represent the 95% CI. Between-group differences over time were analyzed using repeated-measures models accounting for within-patient correlation, with P values adjusted for multiple comparisons. Statistical significance is indicated by asterisks. Statistical significance is indicated by asterisks (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). Abbreviations as in .
    Figure Legend Snippet: Higher Elevated Troponin-I (High-Sensitivity Cardiac Troponin I) Levels Are Associated With Reduced Ejection Fraction (A) High-sensitivity cardiac troponin I (hs-cTnI) and (B) B-type natriuretic peptide (BNP) levels were measured at baseline (pretreatment) and various post-treatment (3, 6, 12, and 24 months). The red line represents mean values at each time point; fold changes were calculated relative to the baseline. Individual patient trajectories are shown as gray lines, with the mean fold change highlighted in red. Longitudinal changes relative to baseline were analyzed using linear mixed-effects models accounting for within-patient correlation, with baseline-referenced post hoc contrasts adjusted for multiple comparisons. Fold changes of (C) LVESV, (D) LVEDV, (E) LVEF, and (F) LVS′ were relative to baseline over time points (3, 6, 12, 24, 30, and 36 months) in patients stratified by high-sensitivity cardiac troponin I levels: troponin ≥0.028 (red line) and troponin <0.028 (blue line). Each point represents an individual patient, with means shown by the lines for each group, and shaded areas represent the 95% CI. Between-group differences over time were analyzed using repeated-measures models accounting for within-patient correlation, with P values adjusted for multiple comparisons. Statistical significance is indicated by asterisks. Statistical significance is indicated by asterisks (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). Abbreviations as in .

    Techniques Used:



    Similar Products

    bnp levels  (Abbott Laboratories)
    86
    Abbott Laboratories bnp levels
    Higher <t>Elevated</t> <t>Troponin-I</t> (High-Sensitivity Cardiac Troponin I) Levels Are Associated With Reduced Ejection Fraction (A) High-sensitivity cardiac troponin I (hs-cTnI) and (B) B-type natriuretic peptide <t>(BNP)</t> levels were measured at baseline (pretreatment) and various post-treatment (3, 6, 12, and 24 months). The red line represents mean values at each time point; fold changes were calculated relative to the baseline. Individual patient trajectories are shown as gray lines, with the mean fold change highlighted in red. Longitudinal changes relative to baseline were analyzed using linear mixed-effects models accounting for within-patient correlation, with baseline-referenced post hoc contrasts adjusted for multiple comparisons. Fold changes of (C) LVESV, (D) LVEDV, (E) LVEF, and (F) LVS′ were relative to baseline over time points (3, 6, 12, 24, 30, and 36 months) in patients stratified by high-sensitivity cardiac troponin I levels: troponin ≥0.028 (red line) and troponin <0.028 (blue line). Each point represents an individual patient, with means shown by the lines for each group, and shaded areas represent the 95% CI. Between-group differences over time were analyzed using repeated-measures models accounting for within-patient correlation, with P values adjusted for multiple comparisons. Statistical significance is indicated by asterisks. Statistical significance is indicated by asterisks (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). Abbreviations as in .
    Bnp Levels, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bnp levels/product/Abbott Laboratories
    Average 86 stars, based on 1 article reviews
    bnp levels - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    baseline bnp levels  (Galectin Therapeutics)
    86
    Galectin Therapeutics baseline bnp levels
    Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus <t>BNP</t> and the clinical model <t>plus</t> <t>galectin-3.</t> The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.
    Baseline Bnp Levels, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/baseline bnp levels/product/Galectin Therapeutics
    Average 86 stars, based on 1 article reviews
    baseline bnp levels - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    stat bnp control level 1  (I-Stat Corporation)
    86
    I-Stat Corporation stat bnp control level 1
    Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus <t>BNP</t> and the clinical model <t>plus</t> <t>galectin-3.</t> The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.
    Stat Bnp Control Level 1, supplied by I-Stat Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stat bnp control level 1/product/I-Stat Corporation
    Average 86 stars, based on 1 article reviews
    stat bnp control level 1 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    stat bnp control level 3  (I-Stat Corporation)
    86
    I-Stat Corporation stat bnp control level 3
    Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus <t>BNP</t> and the clinical model <t>plus</t> <t>galectin-3.</t> The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.
    Stat Bnp Control Level 3, supplied by I-Stat Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stat bnp control level 3/product/I-Stat Corporation
    Average 86 stars, based on 1 article reviews
    stat bnp control level 3 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    stat bnp control level 2  (I-Stat Corporation)
    86
    I-Stat Corporation stat bnp control level 2
    Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus <t>BNP</t> and the clinical model <t>plus</t> <t>galectin-3.</t> The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.
    Stat Bnp Control Level 2, supplied by I-Stat Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stat bnp control level 2/product/I-Stat Corporation
    Average 86 stars, based on 1 article reviews
    stat bnp control level 2 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    stat bnp test i stat bnp control level 1  (I-Stat Corporation)
    86
    I-Stat Corporation stat bnp test i stat bnp control level 1
    Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus <t>BNP</t> and the clinical model <t>plus</t> <t>galectin-3.</t> The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.
    Stat Bnp Test I Stat Bnp Control Level 1, supplied by I-Stat Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stat bnp test i stat bnp control level 1/product/I-Stat Corporation
    Average 86 stars, based on 1 article reviews
    stat bnp test i stat bnp control level 1 - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Higher Elevated Troponin-I (High-Sensitivity Cardiac Troponin I) Levels Are Associated With Reduced Ejection Fraction (A) High-sensitivity cardiac troponin I (hs-cTnI) and (B) B-type natriuretic peptide (BNP) levels were measured at baseline (pretreatment) and various post-treatment (3, 6, 12, and 24 months). The red line represents mean values at each time point; fold changes were calculated relative to the baseline. Individual patient trajectories are shown as gray lines, with the mean fold change highlighted in red. Longitudinal changes relative to baseline were analyzed using linear mixed-effects models accounting for within-patient correlation, with baseline-referenced post hoc contrasts adjusted for multiple comparisons. Fold changes of (C) LVESV, (D) LVEDV, (E) LVEF, and (F) LVS′ were relative to baseline over time points (3, 6, 12, 24, 30, and 36 months) in patients stratified by high-sensitivity cardiac troponin I levels: troponin ≥0.028 (red line) and troponin <0.028 (blue line). Each point represents an individual patient, with means shown by the lines for each group, and shaded areas represent the 95% CI. Between-group differences over time were analyzed using repeated-measures models accounting for within-patient correlation, with P values adjusted for multiple comparisons. Statistical significance is indicated by asterisks. Statistical significance is indicated by asterisks (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). Abbreviations as in .

    Journal: JACC: Basic to Translational Science

    Article Title: Methylated PIH1D1 as a Heart-Specific Biomarker for Anthracycline-Induced Cardiac Remodeling in Breast Cancer Patients

    doi: 10.1016/j.jacbts.2026.101510

    Figure Lengend Snippet: Higher Elevated Troponin-I (High-Sensitivity Cardiac Troponin I) Levels Are Associated With Reduced Ejection Fraction (A) High-sensitivity cardiac troponin I (hs-cTnI) and (B) B-type natriuretic peptide (BNP) levels were measured at baseline (pretreatment) and various post-treatment (3, 6, 12, and 24 months). The red line represents mean values at each time point; fold changes were calculated relative to the baseline. Individual patient trajectories are shown as gray lines, with the mean fold change highlighted in red. Longitudinal changes relative to baseline were analyzed using linear mixed-effects models accounting for within-patient correlation, with baseline-referenced post hoc contrasts adjusted for multiple comparisons. Fold changes of (C) LVESV, (D) LVEDV, (E) LVEF, and (F) LVS′ were relative to baseline over time points (3, 6, 12, 24, 30, and 36 months) in patients stratified by high-sensitivity cardiac troponin I levels: troponin ≥0.028 (red line) and troponin <0.028 (blue line). Each point represents an individual patient, with means shown by the lines for each group, and shaded areas represent the 95% CI. Between-group differences over time were analyzed using repeated-measures models accounting for within-patient correlation, with P values adjusted for multiple comparisons. Statistical significance is indicated by asterisks. Statistical significance is indicated by asterisks (∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001). Abbreviations as in .

    Article Snippet: High-sensitivity cardiac troponin I (hs-cTnI) and BNP levels were measured using chemiluminescent microparticle immunoassays on the Abbott Architect platform (Abbott Laboratories). hs-cTnI was quantified using the Architect STAT High Sensitive Troponin-I assay, while BNP was measured using the Architect BNP assay.

    Techniques:

    Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus BNP and the clinical model plus galectin-3. The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.

    Journal: Clinical Kidney Journal

    Article Title: Galectin-3 as a prognostic biomarker in haemodialysis patients with preserved or mildly reduced ejection fraction

    doi: 10.1093/ckj/sfaf306

    Figure Lengend Snippet: Comparison of predictive performance for the primary composite outcome. ROC curves comparing the discriminative performance of three models for predicting CV death or acute HF hospitalization: a clinical model (age, sex, LVEF, SBP, BMI, DM and hsCRP), the clinical model plus BNP and the clinical model plus galectin-3. The model incorporating galectin-3 yielded the highest AUC, suggesting improved predictive accuracy compared with the others.

    Article Snippet: Galectin-3 was also correlated with baseline BNP levels ( r = 0.229, P < .001).

    Techniques: Comparison